Discussions

Although clinical success has been achieved in a few tumor types, the types of surface proteins that can be targeted by this technology are limited, which severely limits the development of CAR-T cells for multiple tumor types. Besides, the targeted surface proteins so far are also expressed on normal cells, leading to CAR-T-mediated killing of non-cancer cells and potentially life-threatening side effects related to the intensity of the subsequent immune response.